← Back to Stock Screener← Stock Screener
ZYBERNO
Stock Report
Updated Jun 12, 2026

AMICUS THERAPEUTICS, INC. (FOLD)

Healthcare • NASDAQ

$14.49
Amicus Therapeutics Inc. is an American biotechnology company headquartered in Philadelphia, Pennsylvania, that develops therapies for rare metabolic diseases. The company's marketed products include Galafold (migalastat) for Fabry disease (an oral chaperone therapy, the first oral monotherapy approved for a lysosomal storage disease), and Pombiliti + Opfolda for late-onset Pompe disease.

Professional Investment Analysis

ZYBERNO SCORE →
Is it a great business? Is it getting better?
29.0/100
POOR BUSINESS
AMICUS THERAPEUTICS, INC. (FOLD) scores 29/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
MARGIN OF SAFETY
Is this stock cheap or expensive relative to what the business has historically generated for owners?
+97.7%
Undervalued
Is the market underestimating or overestimating what this business is capable of going forward?
-44.6%
Market Overestimates
↑ UNDER
+50%
Brina Gap
-50%
↓ OVER
← OVERVALUED
-100%
Margin of Safety
UNDERVALUED →
+100%
UNDERESTIMATED
GROWTH
DOUBLE
DISCOUNT
EXPENSIVE
HYPE
VALUE
TRAP
0,0
MoS +97.7%  ·  Gap -44.6%

Two independent signals. One tells you if the stock is cheap relative to what the business has historically generated for owners — the Margin of Safety. The other tells you if the market is underestimating what the business is capable of going forward — the Brina Gap.

They are calculated from completely different data sources and answer completely different questions. The Margin of Safety reads the past. The Brina Gap reads the present economics and compares them against what the current stock price is assuming about the future.

When both point in the same direction simultaneously — DOUBLE DISCOUNT — the probability of genuine mispricing is high. The market is wrong on two independent dimensions at once, which is rare and significant.

The most dangerous scenario is not an overvalued stock — those are easy to avoid. It is a VALUE TRAP: a stock that appears cheap historically but where the market is already pricing in stronger growth than the business fundamentals support. Without the Brina Gap signal this looks identical to a genuine opportunity. The matrix separates them instantly.

The Brina Gap is the more powerful of the two signals. Most investors and analytical tools focus on valuation alone — whether a stock is cheap relative to earnings. Far fewer systematically compare what the business economics structurally support against what the stock price is actually assuming. That gap between fundamental growth potential and market expectations is where the most reliable mispricings live, and where this matrix earns its value.

Use this as your first filter. A stock in DOUBLE DISCOUNT territory is worth investigating. Everything else requires either more caution or a specific reason to act.

VALUE TRAP SIGNAL
AMICUS THERAPEUTICS, INC. (FOLD) appears cheap historically (Margin of Safety +97.7%) but the Brina Gap (-44.6%) shows the market already prices in stronger growth than fundamentals support. Verify before acting.
🎯 Expected Annual Return →
323.7%
5-year annualised assuming price converges to intrinsic value
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-12.0%)
Debt-to-Equity (Solvency Risk):POOR (1.58x)
Operating Margin (Operational Efficiency):POOR (5.2%)
Return on Capital (Capital Efficiency):CRITICAL (3.8%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
💎
Intrinsic Value
DCF Fair Value
$618.19
🛡️
Margin of Safety
Valuation Gap
97.7%
🎯
Expected Return
Projected Annual
323.7%
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

According to Zyberno, AMICUS THERAPEUTICS, INC. (FOLD) shows a Value Trap signal — POOR BUSINESS (29/100) with an apparent Margin of Safety of +97.7%, but a Brina Gap of -44.6% reveals the current price still assumes faster growth than the business can deliver.

According to Zyberno's DCF model, AMICUS THERAPEUTICS, INC. (FOLD) trades at $14.49 against an estimated intrinsic value per share of $618.19 — a +97.7% Margin of Safety based on Owner Earnings of $30.40M TTM, projected at 100.0% growth for 10 years with a 2.5% terminal growth rate. The Brina Gap of -44.6% weakens the case: based on the company's ROIC (3.8%) and reinvestment rate (-23.6%), the business can fundamentally grow at -0.9% — but the current enterprise value implies the market expects 43.7%. This places FOLD in the Value Trap quadrant of the Brina Matrix — a value-trap signal where the apparent discount is undermined by overpriced growth expectations. Zyberno's model translates this into a 5-year expected return of 323.7% annually.

Over the trailing twelve months, FOLD generated $30.40M in Owner Earnings. Capital was deployed as follows: $3.30M invested in capital expenditures. Reinvestment rate: -23.6%. Owner Earnings have grown at 100.0% annually over the trailing five years using log-linear regression.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:14.49
Market Cap:$4.47B

Valuation Multiples (3)

P/B Ratio:16.29x
P/S Ratio:7.05x
Peg Ratio:-999.00x

Enterprise Metrics (3)

Enterprise Value:$4.66B
Ev Ebitda Ratio:115.67x
Pfcf Ratio:149.69x
B. Profitability Assessment

Return Metrics (7)

ROE:
-12.0%
📊 Click to view full FOLD ROE analysis →
ROA:-3.2%
Roic:
3.8%
📊 Click to view full FOLD ROIC analysis →
Reinvestment Rate:-23.6%
Fundamental Growth Rate (g):-0.9%
Market-Implied Growth Rate:43.7%
Brina Gap:
-44.6%
☷ Click to view full FOLD Brina Gap analysis →

Margin Analysis (3)

Operating Margin Ttm:5.2%
Net Margin Ttm:-4.3%
Ebitda Margin:6.3%

TTM Performance (3)

Gross Margin Ttm:88.5%
Operating Margin Ttm:5.2%
Net Margin Ttm:-4.3%

Yield Metrics (3)

Earnings Yield:-$0.62
Owner Earnings Yield:$0.68
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

Earnings Surprise (SUE):
-0.80
📊 Click to view full FOLD Earnings Surprise analysis →
EPS Surprise vs Expected:-55.2%
Latest Earnings Filed:2026-02-20

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):25.8%

Cash Flow Growth (Linear) (2)

Free Cash Flow Growth Rate (Linear):100.0%
Operating Cash Flow Growth Rate (Linear):95.9%

Operating Growth (Linear) (1)

Operating Income Growth Rate (Linear):21.5%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.84x
Quick Ratio:1.88x
Cash Ratio:0.90x

Leverage Analysis (3)

Debt To Equity Ttm:1.58x
Debt-to-Equity Ratio:1.58x
Debt To Ebitda:9.97x

Coverage Ratios (2)

Interest Coverage Ratio:0.71x
Times Interest Earned:0.71

Capital Structure (4)

Working Capital:438,345,000.00
Cash And Cash Equivalents:214,010,000.00
Long Term Debt:$392.66M
Net Debt:$187.39M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $634.21M
Linear Growth: 25.8%
📊 Click to view full FOLD Revenue analysis & methodology →
Cost Of Revenue Ttm:$72.93M

Profitability Breakdown (2)

Gross profit TTM: $561.28M
Linear Growth: 25.7%
📊 Click to view full FOLD Gross Profit analysis & methodology →
Operating income TTM: $32.79M
Linear Growth: 21.5%
📊 Click to view full FOLD Operating Income analysis & methodology →

Bottom Line Performance (3)

-$27.11M
Income Before Tax:$191.00K
Ebitda Ttm:40,249,000.00

Operating Expenses (5)

Operating Expenses:528,492,000.00
R And D Expense:135,843,000.00
Sga Expense:383,487,000.00
Income Tax Expense:$27.30M
Interest Expense:46,159,000.00

Expense Ratios (3)

R And D To Revenue Percentage:73.3%
Sga To Revenue Percentage:207.1%
Ebitda Margin:6.3%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$949.87M
Current Assets:$676.17M
Ppe Net:27,108,000.00
Goodwill:197,797,000.00
Intangible Assets:$13.92M

Liability Structure (4)

Total Liabilities:675,629,000.00
Current Liabilities:237,828,000.00
Long Term Debt:$392.66M
Short Term Debt:$8.74M

Equity & Capital (3)

Equity:$274.24M
Retained Earnings:-$2.77B
Common Stock:500,000,000.00

Working Capital Items (3)

Accounts Receivable:115,307,000.00
Inventory:228,819,000.00
Accounts Payable:28,630,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:26,590,000.00
C. Cash Flow Analysis

Operating Activities (2)

Operating cash flow TTM: $33.15M
Linear Growth: 95.9%
Free cash flow TTM: $29.85M
Linear Growth: 100.0%
📊 Click to view full FOLD Free Cash Flow analysis & methodology →

Investment Activities (2)

Investing Cash Flow:-$6.49M
Capital Expenditures Ttm:3,296,000.00

Financing Activities (3)

Financing Cash Flow:$14.03M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:7,460,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.09
-$0.09
Earnings Per Share Ttm:-$0.09

Revenue & Cash Per Share (3)

Sales Per Share Ttm:2.06
Operating Cash Flow Per Share:$0.11
Fcf Per Share Ttm:0.10

Book Value & Capital (2)

Book Value Per Share:$0.89
Cash Per Share:0.69

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.74x
Working Capital Turnover Ttm:1.45x

Receivables Management (2)

Receivables Turnover Ttm:5.50x
Days Sales Outstanding Ttm:66.36

Inventory Management (2)

Inventory Turnover Ttm:0.32x
Days Inventory Outstanding Ttm:1,145.21

Payables & Cash Cycle (2)

Days Payable Outstanding:143.29
Cash Conversion Cycle:1,068.28
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:40.00
Quality Score:35.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (3)

Owner earnings TTM: $30.40M
Linear Growth: 100.0%
📊 Click to view full FOLD Owner Earnings analysis & methodology →
Owner Earnings Per Share:$0.10
Owner Earnings Yield:$0.68

Growth Assessment (1)

Owner Earnings Growth Rate:$100.00

Damodaran Growth Analysis (4)

Reinvestment Rate:-23.6%
Fundamental Growth Rate (g):-0.9%
Market-Implied Growth Rate:43.7%
Brina Gap:
-44.6%
☷ Click to view full FOLD Brina Gap analysis →

Intrinsic Value Models (1)

Intrinsic Value:
$190.63B
📊 Click to view full FOLD DCF valuation →

Margin of Safety (1)

Margin Of Safety:
97.7%
📊 Click to view full FOLD valuation analysis →

Return Scenarios (1)

Theoretical 5-Year Return:
323.7%
📊 Click to view full FOLD expected return analysis →

Investment Assessment (1)

Buffett Assessment:Excellent margin of safety
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (2)

Revenue Growth Rate (Linear):25.8%
Operating Income Growth Rate (Linear):21.5%

Cash Flow Growth Rates (2)

Free Cash Flow Growth Rate (Linear):100.0%
Operating Cash Flow Growth Rate (Linear):95.9%

Other Growth Rates (3)

Gross Profit Growth Rate (Linear):25.7%
Book Value Growth Rate (Linear):-0.1%
Owner Earnings Growth Rate:$100.00
C. Company Profile & Context

Corporate Information (6)

Symbol:FOLD
Company Name:AMICUS THERAPEUTICS, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:308.36M
Shares Outstanding Basic:308.36M
Shares Outstanding Diluted:308.36M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-06-12 09:36:54 UTC
Data Timestamp:2026-06-01T21:53:09.808487
Scroll to Top